ICW Investment Advisors’s AstraZeneca AZN Stock Holding History

ICW Investment Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,000	Closed	-$368K	–	148
2025 Q4	$368K	Hold	2,000	–	–	0.13%	128
2025 Q3	$307K	Hold	2,000	–	–	0.11%	135
2025 Q2	$280K	Hold	2,000	–	–	0.11%	134
2025 Q1	$294K	Hold	2,000	–	–	0.12%	133
2024 Q4	$262K	Buy	+2,000	New	+$280K	0.11%	135

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

ICW Investment Advisors's AZN Position: Q1 2026 in Review

ICW Investment Advisors sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 2,000 shares — an estimated $368K sold.

ICW Investment Advisors first reported a position in AZN in Q4 2024 and held it in 5 quarters. The position peaked at $368K in Q4 2025. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

ICW Investment Advisors reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
ICW Investment Advisors sold 2,000 AstraZeneca shares in Q1 2026, an estimated $368K.
ICW Investment Advisors first reported a position in AstraZeneca in Q4 2024 and held it in 5 quarters.
ICW Investment Advisors's AstraZeneca position peaked at $368K in Q4 2025.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on ICW Investment Advisors's 13F filing for Q1 2026, filed 11 May 2026.